【CLAIMS】

【Claim 1】

A cell therapy pharmaceutical composition for prevention or treatment of occlusive vascular diseases or ulcers resulting therefrom, comprising vascular endothelial progenitor cells and mesenchymal stem cells as active ingredients.

【Claim 2】

The cell therapy pharmaceutical composition of claim 1, wherein the vascular endothelial progenitor cells and the mesenchymal stem cells are human bone marrow-mesenchymal stem cells.

【Claim 3】

The cell therapy pharmaceutical composition of claim 1, wherein the occlusive vascular disease is a disease selected from the group consisting of cerebrovascular disease (CVD), cardiovascular disease, arteriovascular disease, coronary artery disease (CAD) and peripheral artery disease (PAD).

【Claim 4】

The cell therapy pharmaceutical composition of claim 1, wherein the cell therapy product is administered at a dose of 1.2×10^5 to 1.2×10^7 cell/kg body weight.

【Claim 5】

The cell therapy pharmaceutical composition of claim 1, wherein the vascular endothelial progenitor cells are located in vascular cells when administered to a subject.

【Claim 6】

The cell therapy pharmaceutical composition of claim 1, wherein the mesenchymal stem cells are located in pericytes when administered to a subject.

【Claim 7】

A preparation method of a cell therapy product for prevention or treatment of occlusive vascular diseases or ulcers resulting therefrom, comprising mixing vascular endothelial progenitor cells and mesenchymal stem cells.

【Claim 8】

The preparation method of the cell therapy product of claim 7, wherein the vascular endothelial progenitor cells and the mesenchymal stem cells are mixed at a ratio of 2 : 1.

【Claim 9】

The preparation method of the cell therapy product of claim 7, wherein the vascular endothelial progenitor cells and the mesenchymal stem cells are human bone marrow-mesenchymal stem cells.

【Claim 10】

A pharmaceutical composition for prevention or treatment of occlusive vascular diseases or ulcers resulting therefrom, comprising vascular endothelial progenitor cells and mesenchymal stem cells as active ingredients.

【Claim 11】

Use of a compound in the manufacture of a medicament for the treatment of occlusive vascular diseases or ulcers resulting therefrom, wherein the compound comprises vascular endothelial progenitor cells and mesenchymal stem cells as active ingredients.